The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Voclosporin Promising for Lupus Nephritis

Voclosporin Promising for Lupus Nephritis

June 4, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Voclosporin, an investigational calcineurin inhibitor, is currently undergoing Phase 2 clinical trials for the treatment of lupus nephritis.1 The treatment is an immunosuppressant with a synergistic and dual mechanism and the potential to improve short- and long-term outcomes in lupus nephritis when added to standard of care treatments (i.e., mycophenolate mofetil [MMF]). Voclosporin is made by modifying a single amino acid on the cyclosporine molecule, which has a more predictable pharmacokinetic and pharmacodynamic relationship, with an increase in potency and an altered metabolic profile, resulting in the potential for flat dosing.

You Might Also Like
  • Circulating MicroRNA Provides Clues to Class IV Lupus Nephritis
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Lupus Nephritis Guidelines in Progress
Also By This Author
  • FDA Issues Warning for Joint Pain from Diabetes Drugs

In April at the National Kidney Foundation 2017 Spring Clinical Meeting, the results of a global Phase 2B, 48-week study in lupus nephritis were unveiled.2 The study showed low-dose voclosporin (23.7 mg twice daily) was superior to placebo in helping patients achieve complete remission (49% vs. 24%, P<0.001) or partial remission (68% vs. 48%, P=0.007). Additionally, high-dose voclosporin (39.5 mg twice daily) also showed superior results compared with placebo in achieving complete remission (40% vs. 24%, P=0.26) or partial remission (72% vs. 48%, P=0.002).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

All prespecified secondary study endpoints analyzed to date were met at Week 48. These endpoints include the time to complete and partial remission, reduction in Systemic Lupus Erythematosus Disease Activity Index score and reduction in urine protein creatinine ratio. Voclosporin was generally well tolerated with no unexpected safety signals. Renal function measured by eGFR was stable and not significantly different from the study’s control arm. Mean blood pressures were also similar between the two groups.

Phase 3 trials are currently enrolling patients.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Aurinia Pharmaceuticals Inc. News release: Aurinia releases additional 48-week data from the AURA-LV study during late-breaking session at the National Kidney Foundation 2017 Spring Clinical Meetings. 2017 Apr 20.
  2. Aurinia Pharmaceuticals Inc. Aurinia renal response in active lupus with Orelvo (voclosporin) (AURORA). ClincalTrials.gov. 2017 May.

Filed Under: Conditions, SLE (Lupus) Tagged With: calcineurin inhibitor, kidney, Lupus, Lupus nephritis, voclosporin

You Might Also Like:
  • Circulating MicroRNA Provides Clues to Class IV Lupus Nephritis
  • Cure, Effective Treatment for Lupus Nephritis Remain Elusive Despite Advances
  • Lupus Nephritis Guidelines in Progress
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)